This month marks the start of a new era for GlaxoSmithKline, with Emma Walmsley taking over from Sir Andrew Witty – and big pharma's first female CEO has said she is prepared to make tough ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley ... In an early gaffe that ...

Five years into her transformation-focused tenure, Walmsley says the global drugmaker is at last ready to deliver results. She completed the final step of that overhaul this summer, spinning off ...

At the Financial Times (FT) Global Pharma and Biotech Summit in London on 6 November, GSK CEO Emma Walmsley ... and I hope that science and truth will prevail,” concluded Walmsley.

GlaxoSmithKline’s new CEO Emma Walmsley is set to outline her vision for the company alongside half-year results next month – but reports suggest that she may shake up the consumer products ...

On a media call Wednesday morning to discuss her company's fourth-quarter and full-year earnings, CEO Emma Walmsley said that when it came to the British pharma’s infectious disease pipeline ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.